Pulmonary and Critical Care Medicine Ward, the First Affiliated Hospital of Guangxi Medical University, Qingxiu District, Nanning, Guangxi, China.
Tumori. 2021 Jun;107(3):204-208. doi: 10.1177/0300891620941940. Epub 2020 Jul 31.
CircPVT1 was identified as a tumor-promoted circRNA that is upregulated in several cancers. We researched clinical significance of circPVT1 in patients with non-small cell lung cancer (NSCLC) who received cisplatin combined with gemcitabine chemotherapy.
Reverse transcriptase polymerase chain reaction assays were performed to detect circPVT1 expression in 96 patients with NSCLC. In addition, Kaplan-Meier methods were performed to analyze survival of patients with NSCLC.
There is no significant difference between circPVT1 and age, sex, histologic type, lymphatic invasion, or vascular invasion in patients with NSCLC and there is significant difference between circPVT1 and differentiation or p-TNM stage in patients with NSCLC. In addition, after cisplatin combined with gemcitabine chemotherapy, circPVT1 expression was decreased, and circPVT1 expression in the chemotherapy-resistant group was higher than in the chemotherapy-sensitive group. Survival of patients with NSCLC was associated with high circPVT1 expression.
Our study revealed the clinical significance of circPVT1 in NSCLC after cisplatin combined with gemcitabine chemotherapy. After treatment, circPVT1 expression was decreased and circPVT1 expression in chemotherapy-resistant patients was higher than in chemotherapy-sensitive patients. Decreased circPVT1 expression in chemotherapy-sensitive patients is more notable than in chemotherapy-resistant patients. Therefore, it is possible to determine the effect of therapy after receiving chemotherapy by detecting the expression of circRNA in serum.
CircPVT1 被鉴定为一种肿瘤促进的 circRNA，在几种癌症中上调。我们研究了接受顺铂联合吉西他滨化疗的非小细胞肺癌（NSCLC）患者中 circPVT1 的临床意义。
通过逆转录酶聚合酶链反应检测 96 例 NSCLC 患者 circPVT1 的表达。此外，还进行了 Kaplan-Meier 方法分析 NSCLC 患者的生存情况。
circPVT1 与 NSCLC 患者的年龄、性别、组织学类型、淋巴浸润或血管浸润无显著差异，而与 NSCLC 患者的分化或 p-TNM 分期有显著差异。此外，顺铂联合吉西他滨化疗后，circPVT1 的表达降低，化疗耐药组的 circPVT1 表达高于化疗敏感组。NSCLC 患者的生存与高 circPVT1 表达相关。
本研究揭示了 circPVT1 在顺铂联合吉西他滨化疗后 NSCLC 中的临床意义。治疗后，circPVT1 的表达降低，化疗耐药患者的 circPVT1 表达高于化疗敏感患者。化疗敏感患者的 circPVT1 表达降低比化疗耐药患者更为显著。因此，通过检测血清中 circRNA 的表达，有可能在接受化疗后确定治疗效果。
